Table 2.
Response=Square root of plasma ET-1 | ||||
---|---|---|---|---|
| ||||
Estimate (slope, B) | Confidence Interval (95%) | P value | Standardized coefficient (β) | |
Age, years | 0.0064 | 0.0029–0.0098 | 0.0003* | 3.64 |
Female Gender | −0.0973 | −0.1846 to −0.0100 | 0.0290* | −2.19 |
BMI | −0.0022 | −0.0096–0.0050 | 0.5417 | −0.61 |
CAD≥50% | 0.2077 | 0.1253–0.2901 | <0.0001* | 4.96 |
CAD status | <0.0001* | |||
Current smoking | 0.1682 | 0.0897–0.2466 | <0.0001* | 4.22 |
Heart failure status | <0.0001* | |||
Hypertension | −0.1192 | −0.2036 to −0.0347 | 0.0058* | −2.78 |
Diabetes | −0.0400 | −0.1229–0.0427 | 0.3420 | −0.95 |
HBA1C | 0.0021 | −0.020–0.0249 | 0.8523 | 0.19 |
Intervention status | <0.0001* | |||
Preoperative LVEF | −0.0169 | −0.0213 to −0.0126 | <0.0001* | −7.69 |
Indexed LA diameter | 0.2093 | 0.0664–0.3522 | 0.0043* | 2.89 |
LVEF at 30days | −0.0179 | −0.0244 to −0.0114 | <0.0001* | −5.45 |
% Increase in LVEF after 30days | 0.0096 | 0.0053–0.0139 | <0.0001* | 4.41 |
Degree of coronary stenosis | 0.0029 | 0.0019–0.0039 | <0.0001* | 5.96 |
Neutrophil/Lymphocyte ratio | 0.0462 | 0.0290–0.0633 | <0.0001* | 5.32 |
Preoperative use of aspirin | −0.1035 | −0.1903 to −0.0168 | 0.0195* | −2.35 |
Preoperative use of statins | −0.1016 | −0.1813 to −0.0218 | 0.0127* | −2.51 |
Pre operative use of beta blockers | −0.0980 | −0.1775 to −0.0186 | 0.0157* | −2.43 |
Pre operative use of ACEi | −0.0466 | −0.1353–0.0421 | 0.3023 | −1.03 |
Preoperative use of ARBs | −0.1111 | −0.2202 to −0.0019 | 0.0460* | −2.00 |
Preoperative use of Diuretics | 0.0832 | −0.0202–0.1855 | 0.1145 | 1.58 |
CAD status coded as (non-CAD, CAD, MI, MI with acute HF). MI: myocardial infarction, heart failure (HF) coded as (acute HF, chronic HF, no HF), intervention coded as (CABG, PCI, and no intervention) LVEF: left ventricular ejection fraction, LA: left atria, % Increase in LVEF=((LVEF at 30days−LVEF at baseline)/LVEF at baseline)*100, β is the standardized coefficient (slope/std error).